INVO Bioscience Inc (INVO): +312.50% What is going on here?

Reply Private New

Replies (3) Next 10 Prev Next

Send PM Follow Ignore

Followers	2426
Posts	90822
Boards Moderated	7
Alias Born	09/12/2003

powerbattles

Re: None

Wednesday, 04/17/2024 10:37:35 AM

Wednesday, April 17, 2024 10:37:35 AM

+312.50% What is going on here?

Keep Last Read

Replies (3) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent INVO News

Micro Cap Massively Bid Up Before Opening Bell • AllPennyStocks.com • 04/17/2024 02:25:00 PM
INVO Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/16/2024 08:59:29 PM
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:24:52 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:01:07 PM
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 01/16/2024 10:29:59 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:46:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:33 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:29:45 PM
Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/28/2023 10:04:25 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:02:41 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/13/2023 10:08:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:53:21 PM
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal • PR Newswire (US) • 12/11/2023 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:18:38 PM
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • PR Newswire (US) • 11/28/2023 02:00:00 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/24/2023 06:08:33 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:59:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:41 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:04 PM
INVO Reports Record Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 09:01:00 PM
Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 11/13/2023 02:23:51 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:21:54 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/13/2023 02:12:34 PM

More INVO News

InvestorsHub NewsWire

FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover